GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluorine. Its service includes process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conducts pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company